• Je něco špatně v tomto záznamu ?

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

G. Garcia-Manero, V. Santini, A. Almeida, U. Platzbecker, A. Jonasova, LR. Silverman, J. Falantes, G. Reda, F. Buccisano, P. Fenaux, R. Buckstein, M. Diez Campelo, S. Larsen, D. Valcarcel, P. Vyas, V. Giai, EN. Olíva, J. Shortt, D. Niederwieser,...

. 2021 ; 39 (13) : 1426-1436. [pub] 20210325

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004405

PURPOSE: Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia and thrombocytopenia. METHODS: Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI). RESULTS: Two hundred sixteen patients received CC-486 (n = 107) or placebo (n = 109). The median age was 74 years, median platelet count was 25 × 109/L, and absolute neutrophil count was 1.3 × 109/L. In the CC-486 and placebo arms, 31% and 11% of patients, respectively, achieved RBC-TI (P = .0002), with median durations of 11.1 and 5.0 months. Reductions of ≥ 4 RBC units were attained by 42.1% and 30.6% of patients, respectively, with median durations of 10.0 and 2.3 months, and more CC-486 patients had ≥ 1.5 g/dL hemoglobin increases from baseline (23.4% v 4.6%). Platelet hematologic improvement rate was higher with CC-486 (24.3% v 6.5%). Underpowered interim overall survival analysis showed no difference between CC-486 and placebo (median, 17.3 v 16.2 months; P = .96). Low-grade GI events were the most common adverse events in both arms. In the CC-486 and placebo arms, 90% and 73% of patients experienced a grade 3-4 adverse event. Overall death rate was similar between arms, but there was an imbalance in deaths during the first 56 days (CC-486, n = 16; placebo, n = 6), most related to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was 0.57 × 109/L. CONCLUSION: CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. More early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.

Antonio e Biagio e Cesare Arrigo Hospital Alessandria Italy

Bristol Myers Squibb Princeton New Jersey

Celgene a Bristol Myers Squibb Company Boudry Switzerland

Department of Leukemia University of Texas MD Anderson Cancer Center Houston TX

Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Italy

Hematology Fondazione PTV Policlinico Tor Vergata Rome Italy

Hematology Unit Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan Italy

Hôpital St Louis Assistance Publique Hôpitaux de Paris and Université de Paris Paris France

Hospital da Luz Lisboa Lisbon Portugal

Hospital Universitari Vall d'Hebron Barcelona Spain

Hospital Universitario de Salamanca Salamanca Spain

Hospital Universitario Virgen del Rocio Seville Spain

Icahn School of Medicine at Mount Sinai New York NY

Leipzig University Hospital Leipzig Germany

Marienhospital Düsseldorf Düsseldorf Germany

MDS Unit Hematology AOU Careggi University of Florence Florence Italy

Medical Department Hematology Charles University General University Hospital Prague Czech Republic

Monash University and Monash Health Melbourne Australia

MRC Molecular Haematology Unit and Oxford Biomedical Research Centre University of Oxford and Oxford University Hospitals Oxford United Kingdom

Royal Prince Alfred Hospital Sydney Australia

Sackler School of Medicine Tel Aviv University Tel Aviv Israel

Sunnybrook Health Sciences Centre Toronto Canada

Tel Aviv Sourasky Medical Center Tel Aviv Israel

University of Kansas Medical Center Kansas City KS

University of Leipzig Leipzig Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004405
003      
CZ-PrNML
005      
20220127145300.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.20.02619 $2 doi
035    __
$a (PubMed)33764805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Garcia-Manero, Guillermo $u Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
245    10
$a Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes / $c G. Garcia-Manero, V. Santini, A. Almeida, U. Platzbecker, A. Jonasova, LR. Silverman, J. Falantes, G. Reda, F. Buccisano, P. Fenaux, R. Buckstein, M. Diez Campelo, S. Larsen, D. Valcarcel, P. Vyas, V. Giai, EN. Olíva, J. Shortt, D. Niederwieser, M. Mittelman, L. Fianchi, I. La Torre, J. Zhong, E. Laille, D. Lopes de Menezes, B. Skikne, CL. Beach, A. Giagounidis
520    9_
$a PURPOSE: Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia and thrombocytopenia. METHODS: Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI). RESULTS: Two hundred sixteen patients received CC-486 (n = 107) or placebo (n = 109). The median age was 74 years, median platelet count was 25 × 109/L, and absolute neutrophil count was 1.3 × 109/L. In the CC-486 and placebo arms, 31% and 11% of patients, respectively, achieved RBC-TI (P = .0002), with median durations of 11.1 and 5.0 months. Reductions of ≥ 4 RBC units were attained by 42.1% and 30.6% of patients, respectively, with median durations of 10.0 and 2.3 months, and more CC-486 patients had ≥ 1.5 g/dL hemoglobin increases from baseline (23.4% v 4.6%). Platelet hematologic improvement rate was higher with CC-486 (24.3% v 6.5%). Underpowered interim overall survival analysis showed no difference between CC-486 and placebo (median, 17.3 v 16.2 months; P = .96). Low-grade GI events were the most common adverse events in both arms. In the CC-486 and placebo arms, 90% and 73% of patients experienced a grade 3-4 adverse event. Overall death rate was similar between arms, but there was an imbalance in deaths during the first 56 days (CC-486, n = 16; placebo, n = 6), most related to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was 0.57 × 109/L. CONCLUSION: CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. More early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a azacytidin $x aplikace a dávkování $7 D001374
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myelodysplastické syndromy $x farmakoterapie $x patologie $7 D009190
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Santini, Valeria $u MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy
700    1_
$a Almeida, Antonio $u Hospital da Luz Lisboa, Lisbon, Portugal
700    1_
$a Platzbecker, Uwe $u Leipzig University Hospital, Leipzig, Germany
700    1_
$a Jonasova, Anna $u Medical Department Hematology, Charles University General University Hospital, Prague, Czech Republic
700    1_
$a Silverman, Lewis R $u Icahn School of Medicine at Mount Sinai, New York, NY
700    1_
$a Falantes, Jose $u Hospital Universitario Virgen del Rocio, Seville, Spain
700    1_
$a Reda, Gianluigi $u Hematology Unit, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milan, Italy
700    1_
$a Buccisano, Francesco $u Hematology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy
700    1_
$a Fenaux, Pierre $u Hôpital St Louis, Assistance Publique-Hôpitaux de Paris, and Université de Paris, Paris, France
700    1_
$a Buckstein, Rena $u Sunnybrook Health Sciences Centre, Toronto, Canada
700    1_
$a Diez Campelo, Maria $u Hospital Universitario de Salamanca, Salamanca, Spain
700    1_
$a Larsen, Stephen $u Royal Prince Alfred Hospital, Sydney, Australia
700    1_
$a Valcarcel, David $u Hospital Universitari Vall d'Hebron, Barcelona, Spain
700    1_
$a Vyas, Paresh $u MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom
700    1_
$a Giai, Valentina $u Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy
700    1_
$a Olíva, Esther Natalie $u Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
700    1_
$a Shortt, Jake $u Monash University and Monash Health, Melbourne, Australia
700    1_
$a Niederwieser, Dietger $u University of Leipzig, Leipzig, Germany
700    1_
$a Mittelman, Moshe $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel $u Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Fianchi, Luana $u Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
700    1_
$a La Torre, Ignazia $u Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Zhong, Jianhua $u Bristol Myers Squibb, Princeton, New Jersey
700    1_
$a Laille, Eric $u Bristol Myers Squibb, Princeton, New Jersey
700    1_
$a Lopes de Menezes, Daniel $u Bristol Myers Squibb, Princeton, New Jersey
700    1_
$a Skikne, Barry $u Bristol Myers Squibb, Princeton, New Jersey $u University of Kansas Medical Center, Kansas City, KS
700    1_
$a Beach, C L $u Bristol Myers Squibb, Princeton, New Jersey
700    1_
$a Giagounidis, Aristoteles $u Marienhospital Düsseldorf, Düsseldorf, Germany
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 39, č. 13 (2021), s. 1426-1436
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33764805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145256 $b ABA008
999    __
$a ok $b bmc $g 1751770 $s 1155554
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 13 $d 1426-1436 $e 20210325 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace